Celastrus paniculatus for Health & Longevity - Quick Reference Sheet

Celastrus paniculatus for Health & Longevity

Created on 08/25/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 Audit

Oily seed of an Indian vine, long taken as a brain tonic. Animal and cell work agrees: better learning and memory, less anxious behaviour, mood effects resembling a standard antidepressant, nerve cells surviving stress. Human evidence is all but empty. Animal harms: halted sperm production, reversible liver damage; plus user-reported stomach burning, and lead, mercury, arsenic contamination in this category. (Full Review)

Protocol

Modern supplement protocol
400–500 mg, once or twice daily
Capsules of seed powder or water extract. Morning with food is the conventional choice.
Seed oil protocol
5–10 drops, about 250–500 mg
Pressed seed oil with warm water or milk; the form used in most of the rodent behavioural work.
Standard traditional protocol
10 seeds daily, then 15, then 20
Classical titration recorded in the Ayurvedic and Unani pharmacopoeias; each step taken only if no adverse effect appears.
Time to effect
Memory and learning
14–30 days
Rodent benefits required 14–30 days of daily dosing before appearing; single doses are ineffective.
Assessment window
4–8 weeks
The realistic horizon for judging any response. Nothing happens acutely.
Half-life
Never measured in humans
Unmeasured for any constituent. The 14–30 day delay implies gradual adaptation or accumulation rather than acute, single-dose action.

Benefits

Contraindications
  • Pregnancy, any stage
  • Breastfeeding
  • Men attempting conception, or within 74 days of a planned attempt
  • Active peptic ulcer, erosive gastritis, or uncontrolled reflux disease
  • Liver disease, alanine or aspartate aminotransferase above three times the upper limit of normal, or Child-Pugh Class B or C cirrhosis
  • Monoamine oxidase inhibitors (phenelzine, selegiline), or within 14 days of stopping one
  • Children and adolescents under 18
Key Interactions
  • Serotonergic antidepressants: SSRIs (sertraline, fluoxetine)
  • Central nervous system depressants: benzodiazepines (diazepam, lorazepam), sleep agents (zolpidem, eszopiclone), opioids, alcohol
  • Cholinesterase inhibitors: donepezil, rivastigmine, galantamine
  • Lipid-lowering and blood-pressure drugs: statins (atorvastatin, rosuvastatin), antihypertensives
  • Over-the-counter medicines: sedating antihistamines (diphenhydramine, doxylamine), motion-sickness agents, non-steroidal anti-inflammatory drugs (ibuprofen, naproxen)
  • Supplement interactions: cholinergic stacks (alpha-GPC, citicoline, huperzine A), serotonergic supplements (St John's wort, 5-HTP, S-adenosylmethionine), sedative supplements (valerian, kava, melatonin)
  • Other intervention interactions: multi-herb Ayurvedic formulas that already contain Jyotishmati

Risk & Side Effects

  • High:
  • Medium: Heavy-metal contamination of Ayurvedic seed preparations
  • Low: Gastrointestinal irritation and burning; suppression of sperm production; liver injury at high injected doses
  • Speculative: Sedation and next-day dulling; serotonin excess with antidepressants; pregnancy loss

Monitoring

Marker Target Why
Alanine aminotransferase Under 25 U/L (men), under 20 U/L (women) Detects the hepatic injury seen in rodents at high doses
Aspartate aminotransferase Under 25 U/L Confirms and contextualises any alanine aminotransferase rise
Blood lead Under 1 µg/dL, ideally undetectable Screens for the documented contamination of this product category
Low-density lipoprotein cholesterol Under 100 mg/dL, and lower with existing cardiovascular risk Tracks the rodent lipid-lowering signal and any additive effect with statins
High-sensitivity C-reactive protein Under 1.0 mg/L Tracks the anti-inflammatory claim, the plausible route to any felt benefit
Total motile sperm count No established target; change from the individual's own baseline Directly addresses the arrested spermatogenesis found in rats

Cadence: Liver enzymes at 8 weeks, then 6 months, then every 12 months while use continues. Lipid panel and high-sensitivity C-reactive protein at 12 weeks. Semen analysis banked before starting and repeated at 6 months. Blood metals retested only where the product source changes or unexplained symptoms appear.

Qualitative Assessment

  • Recall of names, appointments, and where objects were left, ideally logged rather than remembered
  • Speed and ease of finding words in conversation
  • Baseline anxiety level and how quickly it settles after a stressor
  • Mood stability across the day and week
  • Sleep onset latency and morning alertness, since the sedative signal cuts both ways
  • Stomach comfort in the two hours after dosing, the earliest tolerance signal